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Abstract 
Aim: The aim of this study was to estimate the comparative efficacy and safety of 
antiepileptic drugs (AEDs) in adults with benzodiazepine-resistant convulsive status 
epilepticus (SE). 
Methods: MEDLINE, CENTRAL, ClinicalTrials.gov and Opengrey.eu were searched (from 
inception to 3rd April, 2018) for randomized controlled trials (RCTs) of AEDs used 
intravenously to treat benzodiazepine-resistant SE in adults. Efficacy outcomes were: SE 
cessation within 1 hour from drug administration; seizure freedom at 24 hours. Safety 
outcomes were: respiratory depression; hypotension. Effect sizes were estimated by 
network meta-analyses within a frequentist framework. The hierarchy of competing 
interventions was established using the surface under the cumulative ranking curve (SUCRA) 
and mean ranks. 
Results: Five RCTs were considered, involving 349 patients. Included interventions were 
valproate (VPA; 20-30 mg/kg), phenytoin (PHT; 20 mg/kg), diazepam (DZP; 0.2 mg/kg, then 4 
mg/h), phenobarbital (PHB; 20 mg/kg, then 100 mg every 6 h), lacosamide (LCM; 400 mg) 
and levetiracetam (LEV; 20 mg/kg). PHB was superior to PHT, VPA, DZP, LEV and LCM with 
respect to SE cessation and performed better than VPA, DZP and LCM in the achievement of 
seizure freedom at 24 hours. No differences were noted between drugs in the occurrence of 
respiratory depression and hypotension. According to SUCRA, PHB had the greatest 
probabilities of being best in the achievement of SE control and seizure freedom, whereas 
VPA and LCM ranked best for the safety outcomes. 
Conclusions:  Our study suggests that high-dose PHB is effective in controlling SE and 
preventing seizure recurrence, and LCM and VPA could be better tolerated options. Further 
head-to-head comparative studies are strongly required to provide more definitive evidence.  
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Introduction 
Status epilepticus (SE) is as a condition “resulting either from the failure of the mechanisms 
responsible for seizure termination or from the initiation of mechanisms which lead to 
abnormally, prolonged seizures” [1]. It is a medical and neurological emergency, with long-
term consequences including “neuronal death, neuronal injury, and alteration of neuronal 
networks, depending on the type and duration of seizures” [1]. More specifically, convulsive 
SE is a life-threatening neurological emergency, with a mortality reaching 20% [2]. The 
pharmacological treatment of convulsive SE relies on the use of benzodiazepines as first-line 
agents. In approximately 30-40% of cases, SE can not be adequately controlled by 
benzodiazepines and requires the intravenous (IV) administration of antiepileptic drugs 
(AEDs). The most commonly used agents include phenytoin (PHT), phenobarbital (PHB), 
valproate (VPA), levetiracetam (LEV), and lacosamide (LCM) [3-5].  
To provide useful clinical guidance, it would be important to have data on their comparative 
efficacy and safety. So far, however, very few randomized controlled trials (RCTs) have been 
conducted and the amount of information from direct head-to-head comparisons is very 
limited [6]. The aim of this study was, hence, to systematically and critically appraise the 
extant RCTs of AEDs used to treat benzodiazepine-resistant convulsive SE in adults, and 
estimate their comparative efficacy and safety by means of a network meta-analysis. 
 
Methods 
The study results were reported according to the recommendations of the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement 
for network meta-analyses [7] (Appendix I, supplementary material). The review protocol 
was not previously registered. 
We included RTCs directly comparing any AED administered IV versus any AED as second-line 
treatment for convulsive SE continuing despite benzodiazepine administration 
(benzodiazepine-resistant SE) in adult patients (≥15 years).  
The following electronic databases and data sources were systematically searched: 
1.MEDLINE (January 1966–3rd April 2018), accessed through PubMed; 
2.Cochrane Central Register of Controlled Trials (CENTRAL; accessed 3rd April 2018); 
3.ClinicalTrials.gov (available at: https://clinicaltrials.gov/; accessed 3rd April 2018);  
4. Opengrey.eu (available at: www.opengrey.eu; accessed 3rd April 2018) 
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Search strategy adopted for all the above mentioned databases is reported in Appendix II 
(supplementary material). All resulting titles and abstracts were evaluated, and any relevant 
article was considered. No language restrictions were adopted. We excluded all RCTs 
administering IV AEDs either simultaneously or immediately after benzodiazepines, hence 
without demonstrating refractoriness of SE to benzodiazepines [5]. 
Retrieved articles were independently assessed for inclusion by two review authors (FB, RN); 
any disagreement was resolved through discussion. The methodological quality of all 
included studies and the risk of bias were assessed as outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions version 5.1.0 [updated March 2011] [8]. 
The following trial data were independently extracted by two review authors (FB, RN): main 
study author and age of publication; country; definition of SE; total number, age, and sex of 
participants for each treatment group; history of previous seizures; type of SE; SE duration; 
etiology of SE; details of benzodiazepine administration; details of IV AEDs used as second-
line agents for SE (tested drug and comparator). The following efficacy outcomes were 
considered: cessation of SE following IV AED administration within 1 hour from drug 
administration; seizure freedom at 24 hours. The following safety outcomes were assessed: 
respiratory depression; hypotension. The intent-to-treat population data were used for the 
analyses. First, we did pairwise meta-analyses for all outcomes, using a fixed-effects model. 
Second, we performed network meta-analyses within a frequentist framework assuming 
equal heterogeneity parameter τ across all comparisons [9]. It is appropriate to use NMA if 
the assumption of transitivity (distributions of the potential effect modifiers, like study and 
patient-level covariates, are balanced across all pairwise comparisons) can be defended [10]. 
We assessed the transitivity assumption looking at the similarities of studies in each 
comparison. As not closed loops were present in each network of treatments, we were not 
able to assess the agreement between direct and indirect evidence for a specific comparison 
(consistency assumption) [11]. Effect sizes were estimated as odds ratios (ORs) with their 
95% confidence intervals (CIs). The hierarchy of competing interventions was established 
using the surface under the cumulative ranking curve (SUCRA) and mean ranks [12]. Data 
analysis was performed using STATA/IC 13.1 statistical package (StataCorp LP, College 
Station, TX, USA). 
 
Results 
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A total of 659 records was identified by database and trial registers searching (303 MEDLINE, 
285 CENTRAL, 21 Opengrey.eu, and 50 ClinicalTrials.gov). After excluding duplicates and 
reading title and abstracts, 6 RCTs were initially included [13-18].  One study comparing VPA 
with PHT [13] was eventually excluded, as it provided data on SE control within 7 days of 
administration and this time cut-off was considered to be too long to be clinically 
meaningful. 
Hence, five RCTs were included in our review, involving 349 patients (Fig.1). Following 
comparisons were included: IV VPA versus PHT [14], IV LEV versus PHT [15], IV LCM versus 
VPA [16], diazepam (DZP) versus VPA [17], and PHB versus VPA 30 [18]. Details of included 
interventions (dosages and rate of drug administration) and characteristics of the included 
trials are reported in Table 1. Characteristics of study participants are summarized in Table 2.  
All included studies were conducted in patients with convulsive SE (mostly with generalized 
convulsive SE); etiology and SE duration differed remarkably across studies. The clinical 
definitions of SE adopted were homogeneous between different studies, as well as dosages 
of benzodiazepines administered as first-line treatment. The risks of bias are detailed in 
Table e-1. All studies were not blinded or did not provide details on blinding therefore at 
high risk of performance bias. The risk of detection bias was deemed to be low, since 
outcome measurement (cessation of convulsive SE) was unlikely to be influenced by lack of 
blinding.  
Figure 2 shows the network plots of treatment comparisons for the efficacy and safety 
outcomes. Results of the pairwise meta-analyses are reported in Table e-2. The only 
significant differences were the higher proportions of SE cessation (OR: 5.36; 95% CI: 1.87-
15.36; p=0.002) and seizure freedom at 24 hours (OR: 7.07; 95% CI: 2.52-19.86) in patients 
taking PHB compared to VPA.   
Results of the network meta-analyses of efficacy and safety outcomes are shown in Figure 3. 
PHB was superior to PHT, VPA, DZP, LEV and LCM with respect to SE cessation and 
performed better than VPA, DZP and LCM in the achievement of seizure freedom at 24 
hours. No differences were noted between drugs in the occurrence of respiratory depression 
and hypotension. The comparative effects of all treatments were ranked using SUCRA values 
(Table 3 and Appendix III). According to SUCRA, PHB had the greatest probabilities of being 
best in the achievement of SE control and seizure freedom, whereas VPA and LCM had the 
greatest likelihood ranking best for the safety outcomes.  
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Discussion 
The present study represents the first attempt to perform a systematic analysis of RCTs 
selectively conducted in adults with convulsive SE in whom refractoriness to 
benzodiazepines was clearly reported. The rather strict inclusion criteria were chosen to 
reduce clinical and methodological heterogeneity, with the ultimate aim to provide an 
informative, possibly unbiased, qualitative and quantitative synthesis of the currently 
available evidence. 
Direct comparisons did not find a difference in efficacy between most AEDs, probably 
because of the small number of patients included and the consequent risk of false negative 
results due to statistical error type II. Although it is likely that a difference in efficacy 
between the AEDs exists, one cannot exclude that such difference is of small magnitude and 
requires  a larger number of patients to be demonstrated [19,20]. The only direct 
comparison showing a significant difference in efficacy was the one between PHB and VPA; 
however, this is likely attributable to the high dose of PHB used in the RCT [18].   
Network meta-analyses are not substitutes for clinical trials directly comparing two or more 
drugs but may provide some evidence of their relative efficacy and safety [21,22]. The 
current network meta-analysis of RCTS in benzodiazepine-resistant convulsive SE could offer 
useful information about the hierarchy of competing interventions. Remarkably, PHB 
resulted the most effective treatment in controlling SE, whereas LCM and VPA ranked best 
for the safety outcomes.  
The findings of the present study should be interpreted with caution considering the limited 
number of included studies, their small sample sizes and clinical heterogeneity in SE duration 
and etiology. Differences in dosages should be also taken into account in interpreting the 
results. The high relative efficacy of PHB found in indirect comparisons, both in terms of SE 
cessation within 1 hour from drug administration and lack of SE relapse at 24 hours, is likely 
to reflect the high dose of PHB [18]. Of note, the PHB dose used in this RCT (20 mg/kg, 
followed by 100 mg every 6 hours) was much higher than the maximal dose (15 mg/kg, given 
as single dose) recommended by the recent evidence-based guideline of the American 
Epilepsy Society for the treatment of convulsive SE in children and adults [23]. In addition, 
both VPA and LEV were used at dosages much lower (respectively 20-30 mg/kg and 20 
mg/kg) than those reported by the American Epilepsy Society, which recommends to 
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administer VPA at 40 mg/kg (max. 3000 mg/dose; single dose) and LEV at 60 mg/kg (max. 
4500 mg/dose; single dose) [23]. It is therefore likely that the dosages adopted in the 
included RCTs were too low to detect a significant difference with the active comparator, 
possibly reducing their efficacy. 
Phenytoin ranked worst in the likelihood of reaching SE cessation. This probably reflects the 
need to administer this drug not exceeding the maximum infusion rate of 50 mg/min to 
prevent hypotension and cardiac arrhythmia [3,4]. The related drawback is a long infusion 
time (administering PHT 18–20 mg/kg at 50 mg/min in an adult weighing 70 kg takes 
approximately 0.5 h), which might result in lower seizure control [5,24].  
Although no clear-cut differences were found across treatments in the safety outcomes, VPA 
and LCM were associated with the lowest likelihood to develop respiratory depression and 
hypotension and suggested to be among the better tolerated options. Not surprisingly, PHB 
at such high dosage ranked as the worst treatment with respect to both the safety 
endpoints. Unfortunately, comparisons between different dosages of AEDs to adjust results 
for dose-effects were not feasible due to the very small number of studies, each of them 
evaluating only one single dose of tested drugs. Furthermore, to date there is no information 
on equi-effective doses of AEDs for the treatment of SE, or – more generally – for the 
treatment of epilepsy [22,25]. 
A prior meta-analysis comparing the efficacy of five AEDs in benzodiazepine-resistant 
convulsive SE suggested that VPA, PHB, and LEV can all be used in this condition; the 
evidence was not considered to be sufficiently high to support the use of PHT, whereas no 
enough data were found on LCM [26]. Notably, the results were limited by methodological 
heterogeneity due to the inclusion of both retrospective and prospective controlled trials, 
studies conducted in children and adults, and adopting different definitions of treatment 
response (SE cessation within time frames ranging from 3 minutes up to 48 hours) [27]. 
The present study confirms that the evidence supporting the use of specific AEDs for the 
treatment of benzodiazepine-resistant convulsive SE in adults relies on few RCTs with a small 
number of participants. This emphasizes the need for high-quality and adequately powered 
RCTs to establish the individual role of AEDs in the management of benzodiazepine-resistant 
SE and evaluate whether any of them deserves to be considered as the best agent. 
To date, there are no high-quality, evidence-based data to prefer the use of one AED over 
another in the treatment of benzodiazepine-resistant convulsive SE, and further head-to-
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head comparative studies are urgently needed. The Established Status Epilepticus Treatment 
Trial (ESETT; NCT01960075), funded by the National Institute of Neurological Disorders and 
Stroke, is a large ongoing trial aimed at comparing efficacy and safety of fosphenytoin, VPA 
and LEV in benzodiazepine-resistant SE [28]; in the near future it will hopefully provide 
useful results to inform clinical practice for the treatment of this challenging clinical 
condition. 
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Table 1: Characteristics of included randomized controlled trials. 
 
Study Country Definition(s) of status epilepticus Participants 
and age 
Details of 
benzodiazepine 
administration 
Comparators 
Agarwal et al., 
2007 [14] 
India Continuous convulsive seizure > 5 min 
without recovery of consciousness 
Adults > 18 
years 
DZP 0.2 mg/kg at 2 
mg/min IV, max 20 mg 
PHT 20 mg/kg, max rate: 50 mg/min  VPA 20 mg/kg administered at 40 mg/min 
Chen et al., 
2011 [17] 
China ≥2 seizures without full recovery of 
consciousness between seizures OR 
seizure > 5 min 
Adults ≥ 15 
years 
DZP 0.2 mg/kg given 
twice at a 10-min 
interval 
DZP 0.2 mg/kg at 5 mg/min and then infusion at 
4 mg/h maintained for 3 min and then 
increased every 3 min by 1 lg/kg per min until 
SE control or maximum duration (1 h) of 
administration 
VPA 30 mg/kg at  
6 mg/kg per min followed by a continuous 
infusion at 1–2 mg/kg per h. Infusions 
maintained for at least 6 h after SE control and 
then gradually tapered over 24 h until 
eventually replaced by oral anticonvulsants 
Chakravarthi et 
al., 2015 [15]  
India ≥2 convulsive seizures without full 
recovery of consciousness between 
seizures OR continuous convulsive 
seizure > 5 min  
Adolescents 
and adults 
LZP 0.1 mg/kg at 1 
mg/min IV 
PHT 20 mg/kg with subsequent maintenance 
dose (not further specified), max rate: 50 
mg/min 
LEV 20 mg/kg administered at 100 mg/min with 
subsequent maintenance dose (not further 
specified) 
Su et al., 2016 
[18] 
China ≥2 seizures without full recovery of 
consciousness between seizures OR 
seizure > 5 min 
Adults ≥ 18 
years 
DZP 0.2 mg/kg given 
twice at a 10-min 
interval 
PB 20 mg/kg (an additional 5–10 mg/kg could 
be administered) at 50 mg/min, followed by an 
intravenous dose of 100 mg every 6 h 
(maintained for 24–48 h and then gradually 
tapered replacement with oral AEDs, 24–72 h) 
VPA 30 mg/kg (an additional 15 mg/kg could be 
administered) at 3 mg/kg/min, followed by 
continuous infusion at 1–2 mg/kg (maintained 
for 24–48 h and then gradually tapered 
replacement with oral AEDs, 24–72 h)  
Misra et al., 
2017 [16] 
India Convulsive SE: ≥2 convulsive seizures 
without full recovery or continuous 
convulsions > 5 min. Subtle convulsive SE: 
coma and ictal discharges on EEG and 
subtle convulsive movements 
Adults > 18 
years 
LZP 4 mg in 2-4 min  
IV(repeated once if 
seizures not controlled) 
VPA 30 mg/Kg at 100 mg/min LCM 400 mg at 60 mg/min 
 
DZP: diazepam 
IV: intravenous 
LCM: lacosamide 
LZP: lorazepam 
PB: phenobarbital 
SE: status epilepticus 
VPA: valproate 
Table 2: Clinical characteristics of patients  
 
  
Study No of patients, sex ratio 
(M:F) 
Age 
Mean age±SD 
[range] 
History of previous 
seizures 
Type of SE Seizure 
duration, 
Mean±SD 
[range] 
Etiology of SE 
Agarwal et al., 2007 [14] PHT group 
50 
32:18 
27±15.1 years NR Convulsive SE (semiology not further specified) 
100% 
<2h in 52% 
of patients 
AED withdrawal/noncompliance 28% 
Neurocysticercosis/tuberculoma 24% 
CNS infections 24% 
Primary generalized seizure 12% 
Stroke 4% 
Chronic renal failure 4% 
Eclampsia 4% 
VPA group 
50 
35:15 
27.4±16.8 years NR Convulsive SE (semiology not further specified) 
100% 
<2h in 60% 
of patients 
AED withdrawal/noncompliance 24% 
Neurocysticercosis/tuberculoma 24% 
CNS infections 20% 
Primary generalized seizure 16% 
Stroke 4% 
Extradural hematoma 4% 
Juvenile myoclonic epilepsy 4% 
Brain metastasis 4% 
 
Chen et al., 2011 [17] DZP group      
36 
20:16 
41.14±18.67 NR Generalized convulsive SE 100% 12 patients 
<4 h 
12 patients 
4-14 h 
12 patients > 
24 h 
Epilepsy related 36% 
Viral encephalitis 28% 
Cerebrovascular disease 14% 
Others 22% 
VPA group      
30 
16:14 
40.80±23.18 NR Generalized convulsive SE 100% 11 patients 
<4 h 
9 patients 4-
14 h 
10 patients > 
24 h 
Epilepsy related 33% 
Viral encephalitis 40% 
Cerebrovascular disease 17% 
Others 10% 
Chakravarthi et al., 2015 
[15]  
PHT group      
22 
15:7 
31.82±12.68 years 
 
63.6% Convulsive SE (semiology not further specified) 
100% 
72.05±48.57 
min 
Idiopathic 31.8% 
Acute symptomatic 13.6% 
Remote symptomatic 54.5% 
LEV group      
22 
12:10 
39.00±18.40 years 77.2% Convulsive SE (semiology not further specified) 
100% 
55.91±73.75 
min 
Idiopathic 27.3% 
Acute symptomatic 45.5% 
Remote symptomatic 27.3% 
Su et al., 2016 [18] PB group      
37 
19:18 
37.14±14.98 years NR Generalized convulsive SE 100% 8 patients<4 
h 
29 
patients>4 h 
Epilepsy related 37.8% 
Viral encephalitis 37.8% 
Cerebrovascular disease 8.1% 
Others 16.2% 
VPA group      
36 
20/16 
45.26±18.14 years NR Generalized convulsive SE 100% 10 
patients<4 h 
26 
patients>4 h 
Epilepsy related 25.08% 
Viral encephalitis 44.5% 
Cerebrovascular disease 8.3% 
Others 22.2% 
Misra et al., 2017 [16] LCM group      
33 
21:12 
40 [18-90]  Generalized convulsive SE 90.9% 
Subtle convulsive SE 9.1% 
2 hours 
(median) 
[0.08-160] 
CNS infections 33.3% 
Stroke 30.3% 
Othrs 36.4% 
VPA group      
33 
25:8 
40 [18-85]  Generalized convulsive SE 97% 
Subtle convulsive SE 3% 
2 hours 
(median) 
[0.08-60] 
CNS infections 33.3% 
Stroke 18.2% 
Others 48.5% 
 
AED: antiepileptic drugs 
CNS: central nervous system 
h: hour(s) 
min: minute(s) 
NR: not explicitly reported 
SD: standard deviation 
SE: status epilepticus 
Table 3. Ranking according to SUCRA and mean rank for the efficacy and safety outcomes 
 
a) Status epilepticus cessation 
Treatment SUCRA Mean rank 
PHT 36.8 4.3 
VPA 34.1 4.3 
DZP 47.2 3.6 
LEV 65.9 2.7 
PHB 79.2 2.0 
LCM 44.2 3.8 
 
b) Seizure freedom at 24 hours 
Treatment SUCRA Mean rank 
PHT 53.8 3.3 
VPA 51.1 3.4 
DZP 52.7 3.4 
LEV 22.1 4.9 
PHB 94.9 1.3 
LCM 25.4 4.7 
 
c) Respiratory depression 
Treatment SUCRA Mean rank 
PHT 34.0 4.3 
VPA 77.8 2.1 
DZP 40.8 4.0 
LEV 52.3 3.4 
PHB 18.4 5.1 
LCM 76.7 2.2 
 
d) Hypotension 
Treatment SUCRA Mean rank 
PHT 20.7 4.2 
VPA 74.8 2.0 
DZP 42.6 3.3 
PHB 23.6 4.1 
LCM 88.3 1.5 
 
Abbreviations: DZP=diazepam, LCM=lacosamide, LEV=levetiracetam, PHB=phenobarbital, 
PHT=phenytoin, SUCRA=surface under the cumulative ranking curve, VPA=valproic acid. 
Higher SUCRA values correspond to higher probabilities of better efficacy/tolerability. 
Table 4: Efficacy outcomes of included RCTs (direct comparisons) 
Study SE cessation within 1 hour of drug administration Seizure freedom at 24 hours 
Comparators Statistical difference Comparators Statistical difference 
Agarwal et al., 2007 [14] PHT VPA  PHT VPA  
42/50 44/50 P=0.773 50/50 50/50 P=1 
Chen et al., 2011 [17] DZP VPA  DZP VPA  
20/36 15/30 P=0.652 15/36 12/30 P=0.93 
Chakravarthi et al., 2015 [15]  PHT LEV  PHT LEV  
15/22 13/22 P=0.53 9/22 4/22 P=0.18 
Su et al., 2016 [18] PB VPA  PB VPA  
30/37 16/36 P=0.001 28/37 11/36 P<0.0001 
Misra et al., 2017 [16] LCM VPA  LCM VPA  
21/33 23/33 P=0.79 15/33 20/33 P=0.29 
 
 
AED: antiepileptic drugs 
LCM: lacosamide 
LEV: levetiracetam 
NR: not explicitly reported 
PHT: phenytoin 
SE: status epilepticus 
VPA: valproic acid 
Table e-1: Risk of bias in included randomized controlled trials  
 
Study 
Random 
sequence 
generation 
(selection bias) 
Allocation 
concealment 
(selection bias) 
Blinding of 
participants and 
personnel 
(performance bias) 
Blinding of 
outcome 
assessment 
(detection bias) 
Incomplete 
outcome data 
(attrition bias) 
Selective 
reporting 
(reporting bias) 
Agarwal et al., 
2007 [14] 
Unclear risk 
(not described) 
Unclear risk 
(not described) 
Unclear risk 
(not described) 
Low risk 
(outcome 
measurement 
unlikely to be 
influenced by lack 
of blinding) 
Low risk (no 
missing 
outcome data) 
Unclear risk 
(insufficient 
information to 
permit 
judgement) 
Chen et al., 
2011 [17] 
Low risk (use of 
table of random 
digits) 
Unclear risk 
(not described) 
High risk  
(no blinding) 
Low risk 
(outcome 
measurement 
unlikely to be 
influenced by lack 
of blinding) 
Low risk (no 
missing 
outcome data) 
Unclear risk 
(insufficient 
information to 
permit 
judgement) 
Chakravarthi 
et al., 2015 
[15]  
High risk 
(Sequence 
generation 
depending on 
the order of 
recruitment) 
High risk  
(open random 
allocation 
schedule) 
High risk  
(no blinding) 
Low risk 
(outcome 
measurement 
unlikely to be 
influenced by lack 
of blinding) 
Low risk (no 
missing 
outcome data) 
Unclear risk 
(insufficient 
information to 
permit 
judgement) 
Su et al., 2016 
[18] 
Low risk (use of 
table of random 
digits) 
Low risk  High risk  
(no blinding) 
Low risk 
(outcome 
measurement 
unlikely to be 
influenced by lack 
of blinding) 
Low risk (no 
missing 
outcome data) 
Unclear risk 
(insufficient 
information to 
permit 
judgement) 
Misra et al., 
2017 [16] 
Low risk  
(use of 
computer-
generated 
random 
numbers) 
Unclear risk 
(not described) 
High risk  
(no blinding) 
Low risk 
(outcome 
measurement 
unlikely to be 
influenced by lack 
of blinding) 
Low risk (no 
missing 
outcome data) 
Unclear risk 
(insufficient 
information to 
permit 
judgement) 
 
Table e-2. Results of the pairwise meta-analyses for the efficacy and safety outcomes  
 
a) Status epilepticus cessation 
Comparisons Number 
of studies 
Number of participants 
allocated to any arm 
Odds Ratio              
(95% CI) 
p value 
VPA vs. PHT 1 50, 50 1.40 (0.45-4.37) 0.566 
LEV vs. PHT 1 22, 22 0.67 (0.20-2.32) 0.532 
DZP vs. VPA 1 36, 30 1.25 (0.47-3.30) 0.653 
LCM vs. VPA 1 33, 30 0.76 (0.27-2.12) 0.602 
PHB vs. VPA 1 37, 36 5.36 (1.87-15.36) 0.002 
 
b) Seizure freedom at 24 hours 
Comparisons Number 
of studies 
Number of participants 
allocated to any arm 
Odds Ratio                
(95% CI) 
p value 
VPA vs. PHT 1 50, 50 1.00 (0.02-51.38) 1.000 
LEV vs. PHT 1 22, 22 0.32 (0.08-1.27) 0.106 
DZP vs. VPA 1 36, 30 1.07 (0.40-2.87) 0.891 
LCM vs. VPA 1 33, 30 0.54 (0.20-1.44) 0.219 
PHB vs. VPA 1 37, 36 7.07 (2.52-19.86) <0.001 
 
c) Respiratory depression  
Comparisons Number 
of studies 
Number of participants 
allocated to any arm 
Odds Ratio                
(95% CI) 
p value 
VPA vs. PHT 1 50, 50 0.19(0.01-4.10) 0.291 
LEV vs. PHT 1 22, 22 0.59 (0.14-2.48) 0.474 
DZP vs. VPA 1 36, 30 4.42 (0.20-95.72) 0.344 
LCM vs. VPA 1 33, 30 1.00 (0.38-2.63) 1.000 
PHB vs. VPA 1 37, 36 15.06 (0.82-278.09) 0.068 
 
d) Hypotension  
Comparisons Number 
of studies 
Number of participants 
allocated to any arm 
Odds Ratio                
(95% CI) 
p value 
VPA vs. PHT 1 50, 50 0.07 (0.00-1.24) 0.069 
DZP vs. VPA 1 36, 30 4.42 (0.20-95.72) 0.344 
LCM vs. VPA 1 33, 30 0.32 (0.01-8.23) 0.494 
PHB vs. VPA 1 37, 36 12.35 (0.68-232.15) 0.093 
 
Abbreviations: CI=confidence interval, DZP=diazepam, LCM=lacosamide, LEV=levetiracetam, 
PHB=phenobarbital, PHT=phenytoin, VPA=valproic acid. 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097 
 
For more information, visit www.prisma-statement.org. 
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Figure 2. Network of treatment comparisons for efficacy and safety 
a) Status epilepticus cessation    b) Seizure freedom at 24 hours 
 
c) Respiratory depression       d) Hypotension 
       
The width of the lines is proportional to the inverse of the variance of the comparison 
treatment effect and the size of every circle is proportional to the number of randomly 
assigned participants.  
Abbreviations: DZP=diazepam, LCM=lacosamide, LEV=levetiracetam, PHB=phenobarbital, 
PHT=phenytoin, VPA=valproic acid. 
 
Figure 3. Interval plots for the efficacy and safety outcomes 
a) Status epilepticus cessation 
 
 
b) Seizure freedom at 24 hours 
 
  
c) Respiratory depression 
 
 
d) Hypotension 
 
 
 
Abbreviations: CI=confidence interval, DZP=diazepam, LCM=lacosamide, LEV=levetiracetam, 
PHB=phenobarbital, PHT=phenytoin, VPA=valproic acid. 
 
Highlights 
 
 PHB was superior to PHT, VPA, DZP, LEV and LCM with respect to SE cessation 
 PHB performed better than VPA, DZP and LCM in seizure freedom at 24 hours 
 No differences in the occurrence of respiratory depression and hypotension 
 High-dose PHB is effective in controlling SE and preventing seizure recurrence 
 LCM and VPA could be better tolerated options 
